Tenapanor (BioDeep_00000837584)
代谢物信息卡片
Tenapanor
化学式: C50H66Cl4N8O10S2 (1142.3097216)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CN1CC(C2=C(C1)C(=CC(=C2)Cl)Cl)C3=CC(=CC=C3)S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)C4=CC=CC(=C4)C5CN(CC6=C5C=C(C=C6Cl)Cl)C
InChI: InChI=1S/C50H66Cl4N8O10S2/c1-61-31-43(41-27-37(51)29-47(53)45(41)33-61)35-7-5-9-39(25-35)73(65,66)59-15-19-71-23-21-69-17-13-57-49(63)55-11-3-4-12-56-50(64)58-14-18-70-22-24-72-20-16-60-74(67,68)40-10-6-8-36(26-40)44-32-62(2)34-46-42(44)28-38(52)30-48(46)54/h5-10,25-30,43-44,59-60H,3-4,11-24,31-34H2,1-2H3,(H2,55,57,63)(H2,56,58,64)/t43-,44-/m0/s1
描述信息
A - Alimentary tract and metabolism > A06 - Drugs for constipation > A06A - Drugs for constipation
C78276 - Agent Affecting Digestive System or Metabolism
同义名列表
1 个代谢物同义名
数据库引用编号
5 个数据库交叉引用编号
- KEGGdrug: D11652
- PubChem: 71587953
- DrugBank: DB11761
- ChEMBL: CHEMBL3304485
- CAS: 1234423-95-0
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Giuseppe Cianciolo, Simona Barbuto, Francesca Iacovella, Gaetano La Manna, Andrea Galassi, Paola Ciceri, Mario Cozzolino. An update on tenapanor to treat hyperphosphatemia.
Drugs of today (Barcelona, Spain : 1998).
2022 Jan; 58(1):33-53. doi:
10.1358/dot.2022.58.1.3343689. [PMID: 35107092] - Tiffany Lin, Akram Al-Makki, Brian Shepler. Tenapanor: A new treatment option for hyperphosphatemia in end stage kidney disease.
Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.
2022; 25(?):77-83. doi:
10.18433/jpps32284. [PMID: 35041802] - Geoffrey A Block, Anthony J Bleyer, Arnold L Silva, Daniel E Weiner, Robert I Lynn, Yang Yang, David P Rosenbaum, Glenn M Chertow. Safety and Efficacy of Tenapanor for Long-term Serum Phosphate Control in Maintenance Dialysis: A 52-Week Randomized Phase 3 Trial (PHREEDOM).
Kidney360.
2021 10; 2(10):1600-1610. doi:
10.34067/kid.0002002021. [PMID: 35372979] - Pablo E Pergola, David P Rosenbaum, Yang Yang, Glenn M Chertow. A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY).
Journal of the American Society of Nephrology : JASN.
2021 06; 32(6):1465-1473. doi:
10.1681/asn.2020101398. [PMID: 33766811] - Jerry Yee, David Rosenbaum, Jeffrey W Jacobs, Stuart M Sprague. Small Intestinal Phosphate Absorption: Novel Therapeutic Implications.
American journal of nephrology.
2021; 52(7):522-530. doi:
10.1159/000518110. [PMID: 34515051] - Takashi Shigematsu, Yotaro Une, Kazuaki Ikejiri, Hironori Kanda, Masafumi Fukagawa, Tadao Akizawa. Therapeutic Effects of Add-On Tenapanor for Hemodialysis Patients with Refractory Hyperphosphatemia.
American journal of nephrology.
2021; 52(6):496-506. doi:
10.1159/000516156. [PMID: 34098559] - Andrew J King, Jill Kohler, Cyra Fung, Zhengfeng Jiang, Allison Quach, Padmapriya Kumaraswamy, Glenn M Chertow, David P Rosenbaum. Combination treatment with tenapanor and sevelamer synergistically reduces urinary phosphorus excretion in rats.
American journal of physiology. Renal physiology.
2021 01; 320(1):F133-F144. doi:
10.1152/ajprenal.00137.2020. [PMID: 33283643] - Chia-Ter Chao, Shih-Hua Lin. Uremic Vascular Calcification: The Pathogenic Roles and Gastrointestinal Decontamination of Uremic Toxins.
Toxins.
2020 Dec; 12(12):. doi:
10.3390/toxins12120812. [PMID: 33371477] - Anthony Markham. Tenapanor: First Approval.
Drugs.
2019 Nov; 79(17):1897-1903. doi:
10.1007/s40265-019-01215-9. [PMID: 31677150] - Matthew Saurette, R Todd Alexander. Intestinal phosphate absorption: The paracellular pathway predominates?.
Experimental biology and medicine (Maywood, N.J.).
2019 05; 244(8):646-654. doi:
10.1177/1535370219831220. [PMID: 30764666] - Geoffrey A Block, David P Rosenbaum, Andrew Yan, Glenn M Chertow. Efficacy and Safety of Tenapanor in Patients with Hyperphosphatemia Receiving Maintenance Hemodialysis: A Randomized Phase 3 Trial.
Journal of the American Society of Nephrology : JASN.
2019 04; 30(4):641-652. doi:
10.1681/asn.2018080832. [PMID: 30846557] - Geoffrey A Block, David P Rosenbaum, Andrew Yan, Peter J Greasley, Glenn M Chertow, Myles Wolf. The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2019 02; 34(2):339-346. doi:
10.1093/ndt/gfy061. [PMID: 29617976] - Andrew J King, Matthew Siegel, Ying He, Baoming Nie, Ji Wang, Samantha Koo-McCoy, Natali A Minassian, Qumber Jafri, Deng Pan, Jill Kohler, Padmapriya Kumaraswamy, Kenji Kozuka, Jason G Lewis, Dean Dragoli, David P Rosenbaum, Debbie O'Neill, Allein Plain, Peter J Greasley, Ann-Cathrine Jönsson-Rylander, Daniel Karlsson, Margareta Behrendt, Maria Strömstedt, Tina Ryden-Bergsten, Thomas Knöpfel, Eva M Pastor Arroyo, Nati Hernando, Joanne Marks, Mark Donowitz, Carsten A Wagner, R Todd Alexander, Jeremy S Caldwell. Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability.
Science translational medicine.
2018 08; 10(456):. doi:
10.1126/scitranslmed.aam6474. [PMID: 30158152] - Denis Fouque, Marc Vervloet, Markus Ketteler. Targeting Gastrointestinal Transport Proteins to Control Hyperphosphatemia in Chronic Kidney Disease.
Drugs.
2018 Aug; 78(12):1171-1186. doi:
10.1007/s40265-018-0950-2. [PMID: 30022383] - David P Rosenbaum, Andrew Yan, Jeffrey W Jacobs. Pharmacodynamics, Safety, and Tolerability of the NHE3 Inhibitor Tenapanor: Two Trials in Healthy Volunteers.
Clinical drug investigation.
2018 Apr; 38(4):341-351. doi:
10.1007/s40261-017-0614-0. [PMID: 29363027] - Luca Visconti, Valeria Cernaro, Sebastiano Calimeri, Antonio Lacquaniti, Francesca De Gregorio, Carlo Alberto Ricciardi, Viviana Lacava, Domenico Santoro, Michele Buemi. The Myth of Water and Salt: From Aquaretics to Tenapanor.
Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.
2018 03; 28(2):73-82. doi:
10.1053/j.jrn.2017.06.005. [PMID: 29146141] - Susanne Johansson, David P Rosenbaum, Johan Palm, Bergur Stefansson, Mikael Knutsson, Eleanor A Lisbon, Constanze Hilgendorf. Tenapanor administration and the activity of the H+ -coupled transporter PepT1 in healthy volunteers.
British journal of clinical pharmacology.
2017 Sep; 83(9):2008-2014. doi:
10.1111/bcp.13313. [PMID: 28432691] - Susanne A Johansson, Mikael Knutsson, Maria Leonsson-Zachrisson, David P Rosenbaum. Effect of Food Intake on the Pharmacodynamics of Tenapanor: A Phase 1 Study.
Clinical pharmacology in drug development.
2017 Sep; 6(5):457-465. doi:
10.1002/cpdd.341. [PMID: 28339149] - Susanne Johansson, Maria Leonsson-Zachrisson, Mikael Knutsson, Andrew G Spencer, Eric D Labonté, Desiree Deshpande, Jill Kohler, Kenji Kozuka, Dominique Charmot, David P Rosenbaum. Preclinical and Healthy Volunteer Studies of Potential Drug-Drug Interactions Between Tenapanor and Phosphate Binders.
Clinical pharmacology in drug development.
2017 Sep; 6(5):448-456. doi:
10.1002/cpdd.307. [PMID: 27654985] - Susanne Johansson, David P Rosenbaum, Marie Ahlqvist, Helen Rollison, Mikael Knutsson, Bergur Stefansson, Marie Elebring. Effects of Tenapanor on Cytochrome P450-Mediated Drug-Drug Interactions.
Clinical pharmacology in drug development.
2017 Sep; 6(5):466-475. doi:
10.1002/cpdd.346. [PMID: 28301096] - Geoffrey A Block, David P Rosenbaum, Maria Leonsson-Zachrisson, Magnus Åstrand, Susanne Johansson, Mikael Knutsson, Anna Maria Langkilde, Glenn M Chertow. Effect of Tenapanor on Serum Phosphate in Patients Receiving Hemodialysis.
Journal of the American Society of Nephrology : JASN.
2017 Jun; 28(6):1933-1942. doi:
10.1681/asn.2016080855. [PMID: 28159782] - Susanne Johansson, David P Rosenbaum, Mikael Knutsson, Maria Leonsson-Zachrisson. A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers.
Clinical and experimental nephrology.
2017 06; 21(3):407-416. doi:
10.1007/s10157-016-1302-8. [PMID: 27368672] - Narattaphol Charoenphandhu, Kamonshanok Kraidith, Kornkamon Lertsuwan, Chanakarn Sripong, Panan Suntornsaratoon, Saovaros Svasti, Nateetip Krishnamra, Kannikar Wongdee. Na+/H+ exchanger 3 inhibitor diminishes hepcidin-enhanced duodenal calcium transport in hemizygous β-globin knockout thalassemic mice.
Molecular and cellular biochemistry.
2017 Mar; 427(1-2):201-208. doi:
10.1007/s11010-016-2911-y. [PMID: 27995414] - Baris Afsar, Nosratola D Vaziri, Gamze Aslan, Kayhan Tarim, Mehmet Kanbay. Gut hormones and gut microbiota: implications for kidney function and hypertension.
Journal of the American Society of Hypertension : JASH.
2016 12; 10(12):954-961. doi:
10.1016/j.jash.2016.10.007. [PMID: 27865823] - Geoffrey A Block, David P Rosenbaum, Maria Leonsson-Zachrisson, Bergur V Stefansson, Tina Rydén-Bergsten, Peter J Greasley, Susanne A Johansson, Mikael Knutsson, Björn C Carlsson. Effect of Tenapanor on Interdialytic Weight Gain in Patients on Hemodialysis.
Clinical journal of the American Society of Nephrology : CJASN.
2016 09; 11(9):1597-605. doi:
10.2215/cjn.09050815. [PMID: 27340281] - Eric D Labonté, Christopher W Carreras, Michael R Leadbetter, Kenji Kozuka, Jill Kohler, Samantha Koo-McCoy, Limin He, Edward Dy, Deborah Black, Ziyang Zhong, Ingrid Langsetmo, Andrew G Spencer, Noah Bell, Desiree Deshpande, Marc Navre, Jason G Lewis, Jeffrey W Jacobs, Dominique Charmot. Gastrointestinal Inhibition of Sodium-Hydrogen Exchanger 3 Reduces Phosphorus Absorption and Protects against Vascular Calcification in CKD.
Journal of the American Society of Nephrology : JASN.
2015 May; 26(5):1138-49. doi:
10.1681/asn.2014030317. [PMID: 25404658] - Andrew G Spencer, Eric D Labonte, David P Rosenbaum, Craig F Plato, Christopher W Carreras, Michael R Leadbetter, Kenji Kozuka, Jill Kohler, Samantha Koo-McCoy, Limin He, Noah Bell, Jocelyn Tabora, Kristin M Joly, Marc Navre, Jeffrey W Jacobs, Dominique Charmot. Intestinal inhibition of the Na+/H+ exchanger 3 prevents cardiorenal damage in rats and inhibits Na+ uptake in humans.
Science translational medicine.
2014 Mar; 6(227):227ra36. doi:
10.1126/scitranslmed.3007790. [PMID: 24622516]